FNA Quote, Financials, Valuation and Earnings

Alphatec Holdings has a net margin of -15.5% compared to Paragon 28's net margin of -18.85%. Paragon 28's return on equity of -36.38% beat Alphatec Holdings's return on equity of -691.37%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.62%. On the other hand Alphatec Holdings has an analysts' consensus of $18.04 which suggests that it could grow by 85.04%. Given that Alphatec Holdings has higher upside potential than Paragon 28, analysts believe Alphatec Holdings is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.205, suggesting its more volatile than the S&P 500 by 20.514%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Alphatec Holdings quarterly revenues of $176.8M. Paragon 28's net income of -$11.1M is higher than Alphatec Holdings's net income of -$33.3M. Notably, Paragon 28's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.22x versus 2.28x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -15.5% compared to Paragon 28's net margin of 4.39%. Paragon 28's return on equity of -36.38% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.62%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $24.75 which suggests that it could grow by 45.67%. Given that Integra Lifesciences Holdings has higher upside potential than Paragon 28, analysts believe Integra Lifesciences Holdings is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.12%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Paragon 28's net income of -$11.1M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Paragon 28's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.22x versus 0.81x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -15.5% compared to Paragon 28's net margin of -17.66%. Paragon 28's return on equity of -36.38% beat KORU Medical Systems's return on equity of -32.71%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.62%. On the other hand KORU Medical Systems has an analysts' consensus of $5.70 which suggests that it could grow by 147.83%. Given that KORU Medical Systems has higher upside potential than Paragon 28, analysts believe KORU Medical Systems is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.827%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Paragon 28 pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Paragon 28 quarterly revenues are $71.7M, which are larger than KORU Medical Systems quarterly revenues of $8.8M. Paragon 28's net income of -$11.1M is lower than KORU Medical Systems's net income of -$1.6M. Notably, Paragon 28's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.22x versus 3.13x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of -15.5% compared to Paragon 28's net margin of 11.84%. Paragon 28's return on equity of -36.38% beat Zimmer Biomet Holdings's return on equity of 7.21%.

Paragon 28 has a consensus price target of $14.50, signalling upside risk potential of 11.62%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $122.31 which suggests that it could grow by 19.5%. Given that Zimmer Biomet Holdings has higher upside potential than Paragon 28, analysts believe Zimmer Biomet Holdings is more attractive than Paragon 28.

Paragon 28 has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.664%.

Paragon 28 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 0.94% to investors and pays a quarterly dividend of $0.24 per share. Paragon 28 pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Paragon 28 quarterly revenues are $71.7M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. Paragon 28's net income of -$11.1M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, Paragon 28's price-to-earnings ratio is -- while Zimmer Biomet Holdings's PE ratio is 23.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Paragon 28 is 4.22x versus 2.72x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.